Atom Investors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$221K Sell
6,850
-829
-11% -$30.7K 0.02% 598
2025
Q4
$323K Hold
7,679
0.03% 432
2025
Q3
$264K Sell
7,679
-6,364
-45% -$183K 0.02% 461
2025
Q2
$380K Buy
+14,043
New +$407K 0.03% 395
2024
Q2
Sell
-51,287
Closed -$1.14M 681
2024
Q1
$1.14M Buy
51,287
+3,488
+7% +$85.1K 0.14% 205
2023
Q4
$1.31M Sell
47,799
-15,750
-25% -$380K 0.23% 144
2023
Q3
$1.42M Buy
63,549
+16,935
+36% +$436K 0.32% 96
2023
Q2
$1.19M Buy
46,614
+2,031
+5% +$49.2K 0.45% 49
2023
Q1
$994K Buy
+44,583
New +$1.08M 0.54% 43
2022
Q4
Sell
-18,126
Closed -$301K 325
2022
Q3
$301K Buy
+18,126
New +$408K 0.11% 186
2020
Q2
Sell
-79,396
Closed -$2M 488
2020
Q1
$2M Sell
79,396
-106,120
-57% -$2.67M 0.18% 112
2019
Q4
$5.18M Buy
185,516
+17,018
+10% +$441K 0.42% 76
2019
Q3
$4.04M Buy
168,498
+25,915
+18% +$689K 0.28% 112
2019
Q2
$4.07M Sell
142,583
-446,305
-76% -$11.1M 0.26% 122
2019
Q1
$14.7M Buy
588,888
+98,811
+20% +$1.89M 1.25% 13
2018
Q4
$6.17M Buy
+490,077
New +$5.8M 0.61% 30

Other funds holding VCYT

Atom Investors's VCYT Position: Q1 2026 in Review

Atom Investors reduced its Veracyte (VCYT) stake by 11% in Q1 2026, selling an estimated $30.7K and leaving 6,850 shares worth $221K. The position accounts for 0.02% of the portfolio, ranked #598.

Atom Investors first reported a position in VCYT in Q4 2018 and has held it in 16 quarters since. The position peaked at $14.7M in Q1 2019. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • Atom Investors held 6,850 shares of Veracyte worth $221K as of Q1 2026.
  • Atom Investors sold 829 Veracyte shares in Q1 2026, an estimated $30.7K.
  • Veracyte made up 0.02% of Atom Investors's portfolio in Q1 2026, its #598 holding.
  • Atom Investors first reported a position in Veracyte in Q4 2018 and has held it in 16 quarters since.
  • Atom Investors's Veracyte position peaked at $14.7M in Q1 2019.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.